Literature DB >> 21153921

Tumor necrosis factor-α: investigation of gene polymorphism and regulation of TACE-TNF-α system in patients with acute myocardial infarction.

Sayyed Mohammad Hossein Ghaderian1, Reza Akbarzadeh Najar, Akram Sadat Tabatabaei Panah.   

Abstract

A polymorphism within tumor necrosis factor-α (TNF-α) gene promoter and contribution of TNF-α converting enzyme (TACE) have been reported to be associated with TNF-α production which may increase susceptibility to heart failure such as acute myocardial infarction (AMI). However, the relationship between this polymorphism and susceptibility to AMI and the mechanism of TACE-TNF-α system regulation has poorly been studied. Genomic DNA and peripheral blood mononuclear cells (PBMCs) of patients with AMI and control subjects was extracted. The -308 G/A TNF-α polymorphism was detected. The mRNA transcription and protein expression levels of TNF-α and TACE were analyzed by real time RT-PCR and flow cytometry respectively as well as plasma TNF-α by ELISA. The 'A' allele frequency of TNF-α was significantly more frequent in the patients than controls (P < 0.001). There were statistically significant differences in TNF-α and TACE mRNA and protein levels as well as circulating TNF-α in the patients. However, these levels were higher in the patients who carry 'A' allele. There were significant positive correlation between these mRNAs and protein expression levels (r = 0.66, P < 0.001, r = 0.78, P < 0.001 respectively). These data suggest that genetic polymorphism in TNF-α might be helpful for determining susceptibility to AMI in Iranian patients. The TACE-TNF-α system in circulating leucocytes is stimulated which these results demonstrate that in patients with AMI, TACE expression in PBMC increases with TNF-α expression and processing of TNF-α in PBMC might be regulated by TACE at transcriptional, translational, and post-translational levels in AMI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21153921     DOI: 10.1007/s11033-010-0641-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  34 in total

1.  Effects of metoprolol treatment on a disintegrin metalloproteinase expression and extracellular matrix remodeling after myocardial infarction in rats.

Authors:  Juan Zhao; Xiu-Fen Qu; Chun-Yu Zhao; Feng-Lin Cao; Tao Zhou; Wei-Min Li; Yong-Lin Huang
Journal:  Chin Med J (Engl)       Date:  2007-09-05       Impact factor: 2.628

2.  Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha.

Authors:  M L Moss; S L Jin; M E Milla; D M Bickett; W Burkhart; H L Carter; W J Chen; W C Clay; J R Didsbury; D Hassler; C R Hoffman; T A Kost; M H Lambert; M A Leesnitzer; P McCauley; G McGeehan; J Mitchell; M Moyer; G Pahel; W Rocque; L K Overton; F Schoenen; T Seaton; J L Su; J D Becherer
Journal:  Nature       Date:  1997-02-20       Impact factor: 49.962

3.  Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction.

Authors:  P M Ridker; N Rifai; M Pfeffer; F Sacks; S Lepage; E Braunwald
Journal:  Circulation       Date:  2000-05-09       Impact factor: 29.690

4.  Detection and localization of tumor necrosis factor in human atheroma.

Authors:  P Barath; M C Fishbein; J Cao; J Berenson; R H Helfant; J S Forrester
Journal:  Am J Cardiol       Date:  1990-02-01       Impact factor: 2.778

5.  Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans.

Authors:  E Louis; D Franchimont; A Piron; Y Gevaert; N Schaaf-Lafontaine; S Roland; P Mahieu; M Malaise; D De Groote; R Louis; J Belaiche
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

6.  Polymorphisms of the tumour necrosis factor-alpha gene, coronary heart disease and obesity.

Authors:  S M Herrmann; S Ricard; V Nicaud; C Mallet; D Arveiler; A Evans; J B Ruidavets; G Luc; L Bara; H J Parra; O Poirier; F Cambien
Journal:  Eur J Clin Invest       Date:  1998-01       Impact factor: 4.686

Review 7.  Platelet-leukocyte-endothelial interactions in coronary artery disease.

Authors:  J L Mehta; F A Nicolini; W H Donnelly; W W Nichols
Journal:  Am J Cardiol       Date:  1992-03-06       Impact factor: 2.778

Review 8.  The cell in shock: the origin of multiple organ failure.

Authors:  G Schlag; H Redl; S Hallström
Journal:  Resuscitation       Date:  1991-04       Impact factor: 5.262

9.  Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation.

Authors:  A G Wilson; J A Symons; T L McDowell; H O McDevitt; G W Duff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

10.  Endothelial nitric-oxide synthase enhances lipopolysaccharide-stimulated tumor necrosis factor-alpha expression via cAMP-mediated p38 MAPK pathway in cardiomyocytes.

Authors:  Tianqing Peng; Xiangru Lu; Ming Lei; Qingping Feng
Journal:  J Biol Chem       Date:  2002-12-27       Impact factor: 5.157

View more
  10 in total

1.  C-reactive protein (CRP) gene polymorphisms: implication in CRP plasma levels and susceptibility to acute myocardial infarction.

Authors:  Reza Akbarzadeh Najar; Sayyed Mohammad Hossein Ghaderian; Akram Sadat Tabatabaei Panah
Journal:  Mol Biol Rep       Date:  2011-07-01       Impact factor: 2.316

2.  IL12B and IL23R polymorphisms are associated with alopecia areata.

Authors:  Pardis-Sadat Tabatabaei-Panah; Hamideh Moravvej; Sara Delpasand; Mona Jafari; Sanaz Sepehri; Reyhaneh Abgoon; Ralf J Ludwig; Reza Akbarzadeh
Journal:  Genes Immun       Date:  2020-05-01       Impact factor: 2.676

3.  Risk of obesity and type 2 diabetes with tumor necrosis factor-α 308G/A gene polymorphism in metabolic syndrome and coronary artery disease subjects.

Authors:  Ranbir Chander Sobti; Rupinder Kler; Yash Paul Sharma; Kewal Krishan Talwar; Neha Singh
Journal:  Mol Cell Biochem       Date:  2011-11-13       Impact factor: 3.396

Review 4.  Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease.

Authors:  Boris Decourt; Debomoy K Lahiri; Marwan N Sabbagh
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

5.  Association between the TNF-α G-308A polymorphism and risk of ischemic heart disease: a meta-analysis.

Authors:  Jiarong Wang; Yazhou He; Yang Yang; Tiange Song; Nan Chen; Yanhong Zhou
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 6.  Tumor necrosis factor-alpha gene polymorphisms and susceptibility to ischemic heart disease: A systematic review and meta-analysis.

Authors:  Peng Zhang; Xiaomei Wu; Guangxiao Li; Qiao He; Huixu Dai; Cong Ai; Jingpu Shi
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

7.  Effects of the IL6 -174G>C promoter polymorphism and IL-6 serum levels on the progression of cutaneous malignant melanoma.

Authors:  Tatyana Vlaykova; Mateuzh Kurzawski; Tanya Tacheva; Dimo Dimov; Asen Anastasov; Denitsa Vlaykova; Ani Miteva; Niamh O'donoghue; Marek Drozdzik
Journal:  Oncol Lett       Date:  2020-06-16       Impact factor: 2.967

8.  Proinflammatory Cytokine Gene Polymorphisms in Bullous Pemphigoid.

Authors:  Pardis-Sadat Tabatabaei-Panah; Hamideh Moravvej; Zahra Sadaf; Hadis Babaei; Maryam Geranmayeh; Sedigheh Hajmanouchehri; Ahmad Karimi; Fatemeh Sajjadi; Fereshteh Arghand; Ralf J Ludwig; Mareike Witte; Reza Akbarzadeh
Journal:  Front Immunol       Date:  2019-03-29       Impact factor: 7.561

9.  Gene polymorphism associated with TNF-α (G308A) IL-6 (C174G) and susceptibility to coronary atherosclerotic heart disease: A meta-analysis.

Authors:  Jiang Yuepeng; Xiaoxuan Zhao; Yang Zhao; Liu Li
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

Review 10.  The renin-angiotensin system: going beyond the classical paradigms.

Authors:  Robson Augusto Souza Santos; Gavin Y Oudit; Thiago Verano-Braga; Giovanni Canta; Ulrike Muscha Steckelings; Michael Bader
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-02-01       Impact factor: 4.733

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.